e sabong jay costura
Matt Taylor has confessed he was "so disappointed" with his Bristol Rovers team's second half performance in particular in a drab 2-0 home defeat to Blackpool. The Gas left their home pitch with zero shots on target over almost 100 minutes of football having created few clear cut opportunities of note. Rovers did actually start the game brightly but having offered limited threat, the game's momentum started to shift in the visitors' favour as Josh Griffiths denied Dom Ballard before Bryant Bilongo was deemed to have headed a free-kick into his own net with clarity still yet to be provided at the time of writing. Once again, the hosts started the second period satisfactorily but a penalty given for a James Wilson handball was converted by Lee Evans which completely sapped any remaining belief from the Gas. Reflecting on the game post-match, Taylor said: "Some bright moments in the first half, but not enough, and certainly some of those moments didn't turn into any substance of chances or sustained pressure. Yeah, we conceded the best chance of the first half and then obviously the goal makes us feel worse than what we needed to at half-time. "Second half, I was so, so disappointed. We actually started the second half relatively brightly and then one ricochet in the middle of the pitch and all of a sudden we're defending a battle, trying to keep out a penalty. And then from that point we went for the next 15, 20 minutes. We just had no control of the game whatsoever. "Wrestled it back towards the end, but without creating anything and they got bodies behind the ball really well. It felt like the pitch was a little bit too big for us tonight. It looked a little bit like we were half a yard short all over the pitch and then we could never really get close to the game. "Goals always rock you, especially at home, especially with this group," the Gas manager added. "But in terms of chance creation, there weren't clear chances. There weren't chances of quality. I just said to them, I have to always be honest, I remember one pass all night which I thought was a good pass." The biggest frustration was the fact that Rovers had played well and recorded an impressive 1-0 win away at Mansfield Town three days prior with the same team bar Bilongo for Clinton Mola as the team's strive for consistency continues. Next up is a trip to Barnsley in the FA Cup second round on Saturday with the Gas' next League One outing being a trip to Leyton Orient next Tuesday night.Donna T. from Bismarck, North Dakota, writes: “When the variety of fresh veggies is limited, I buy frozen. I do, however, like to keep store-purchased canned veggies in my pantry and use them in tight squeezes. I am confused by statements that canned veggies are highly nutritious and comparable to frozen. Comparing nutrition labels does not seem to support this statement. I would so appreciate your input.” Fresh veggies certainly are best if available — and if they don’t lose precious nutrients by overcooking or languishing too long in the fridge. But don’t feel bad about using frozen and canned varieties, too. They are picked at the peak of ripeness and generally processed right away, which helps maintain nutrients. In fact, the current 2020-2025 Dietary Guidelines for Americans encourage us to eat a variety of vegetables including “fresh, frozen and canned.” While frozen and canned veggies both have their place, some facts about canned goods may surprise you. For one, they may literally save your life in an emergency when refrigerated food is not available. What about sodium? According to the Canned Food Alliance (mealtime.org), salt or sodium is not used to preserve canned food. That’s done with heat and cooling. So it’s OK to look for lower-sodium versions if needed. Or you can simply drain and rinse beans and other canned vegetables to get rid of 40% or more of the added sodium. Interestingly, according to the Centers for Disease Control and Prevention, the major sources of sodium in our food are pizza, cold cuts, cured meat, bread, rolls, burgers and sandwiches. Canned food is not even in the top 10. What about nutrients and other beneficial substances? Some, such as lycopene (the healthful red pigment in tomatoes) and beta carotene (which converts to vitamin A in the body), are actually enhanced in heat-processed canned vegetables. Vitamin C is another story. It is the least stable of all vitamins and is easily destroyed by heat and exposure to air. However, according to a 2021 review in the journal Antioxidants, new technologies can now preserve the vitamin C content in many canned foods. I have a can of 100% vegetable juice in my cupboard, and it contains more vitamin C than a medium orange. “The general conclusion of this review,” say these authors, “was that while canned foods are often perceived as less nutritious than fresh or frozen products, the research reveals that this is not always true.” Susan C. from Lynchburg, Virginia, responded to a recent column about feeding picky grandkids: “You said you always want to throw in a vegetable and that you saw a tomato on your counter. I was always told that a tomato is really a fruit. Isn’t that true?” It is true. Tomatoes are biologically fruits but nutritionally vegetables. In fact, tomatoes were officially classified as vegetables by the U.S. Supreme Court in 1893. It’s a great trivia question for grandkids. Barbara Intermill is a registered dietitian. Email her at barbara@quinnessentialnutrition.com . Get local news delivered to your inbox!
Beer and tequila from Mexico, whisky from Canada could cost more with Trump's tariffsTight race for the North Carolina Supreme Court is heading to another recount
Riley scores 18, Utah Tech beats Denver 68-54Malik Nabers says calling the Giants 'soft' was wrong but he doesn't regret speaking out
New York, USA, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Global Peripheral Artery Disease Treatment Market to Grow at a CAGR of ~7% by 2030 | DelveInsight The demand for peripheral artery disease treatment is mainly driven by the increasing prevalence of PAD and arteriosclerosis, alongside the rising rates of obesity, diabetes, and hypertension. Additionally, the growing aging population and the increasing preference for minimally invasive procedures are contributing factors to this trend during the forecast period from 2024 to 2030. DelveInsight’s Peripheral Artery Disease Treatment Market Insights report provides the current and forecast market analysis, individual leading peripheral artery disease treatment companies’ market shares, challenges, peripheral artery disease treatment market drivers, barriers, trends, and key market peripheral artery disease treatment companies in the market. Key Takeaways from the Peripheral Artery Disease Treatment Market Report As per DelveInsight estimates, North America is anticipated to dominate the global peripheral artery disease treatment market during the forecast period. In the treatment type segment of the PAD treatment market, the angioplasty balloons in the devices category had a significant revenue share of 43% in the PAD treatment market in 2023. Notable peripheral artery disease treatment companies such as Medtronic, Koninklijke Philips N.V., B. Braun SE, Boston Scientific Corporation, BD, Terumo Corporation, Biotronik, Cordis, Abbott, AngioDynamics, Cardiovascular Systems, Inc., Bluesail Medical Co., Ltd., Contego Medical, Inc., Argon Medical, REX Medical, Merck & Co., Inc., Sanofi, Johnson and Johnson Services, Inc., Otivio, Reflow Medical Inc., and several others, are currently operating in the peripheral artery disease treatment market. In March 2024, BD (Becton, Dickinson and Company), a leading global medical technology company, announced enrollment of the first patient in the investigational device exemption (IDE) study, "AGILITY," which assessed the safety and effectiveness of the BD Vascular Covered Stent for the treatment of Peripheral Arterial Disease (PAD). In October 2023, Cardio Flow, Inc. , a privately held medical device company and developer of minimally invasive devices to treat peripheral artery disease (PAD), announced that it received U.S. Food and Drug Administration (FDA) 510(k) clearance for its FreedomFlow Orbital Atherectomy Peripheral Platform. In June 2023, Endologix announced that it received FDA approval for its Detour system to treat long, complex superficial femoropopliteal lesions. It treats complex peripheral artery disease by allowing physicians to bypass lesions in the superficial femoral artery by using stents routed through the femoral vein to restore blood flow to the leg. To read more about the latest highlights related to the peripheral artery disease treatment market, get a snapshot of the key highlights entailed in the Global Peripheral Artery Disease Treatment Market Report Peripheral Artery Disease Treatment Overview Peripheral artery disease (PAD) is a common circulatory condition where narrowed arteries reduce blood flow to the limbs, leading to symptoms like leg pain, cramping, and in severe cases, tissue damage. Treatment for PAD generally focuses on managing symptoms, improving blood flow, and reducing risk factors like high blood pressure, high cholesterol, and diabetes. Lifestyle changes such as smoking cessation, regular exercise, and a healthy diet are fundamental in preventing further progression of the disease. Medications may include antiplatelet drugs, such as aspirin, to reduce the risk of clot formation, as well as statins to control cholesterol levels. In some cases, medications like cilostazol or pentoxifylline can help improve walking distance by enhancing blood flow. For more advanced cases of PAD, where lifestyle modifications and medications are insufficient, invasive interventions may be necessary. These can include angioplasty, where a balloon is used to open narrowed arteries, or the placement of stents to keep the arteries open. In severe instances, surgical bypass procedures may be required to reroute blood around blocked arteries. Endovascular techniques, such as atherectomy, where plaques are removed, can also be used to restore proper blood circulation. Additionally, PAD patients are closely monitored for complications such as ulcers or wounds that may not heal properly due to poor circulation, with specialized wound care and, if necessary, amputation being the last resort. Peripheral Artery Disease Treatment Market Insights In 2023, North America held the largest share of 44% in the global peripheral artery disease treatment market. This growth is driven by increasing government efforts to raise awareness about effective PAD treatments, the rising number of elderly patients, and the growing prevalence of obesity, hypertension, and diabetes. Additionally, the region’s advanced healthcare infrastructure is further supporting the expansion of the PAD market in North America. To know more about why North America is leading the market growth in the peripheral artery disease treatment market, get a snapshot of the Peripheral Artery Disease Treatment Market Outlook Peripheral Artery Disease Treatment Market Dynamics The peripheral artery disease treatment market is experiencing robust growth driven by the increasing prevalence of the condition and advancements in therapeutic approaches . PAD is a common vascular disorder, particularly among aging populations and individuals with risk factors such as diabetes, hypertension, and smoking. As the global geriatric population continues to rise , the demand for effective treatments, ranging from medical therapies to surgical interventions, has surged. This market is highly competitive , with key players investing in innovative therapies and products designed to alleviate symptoms, prevent complications, and improve the quality of life for patients. The treatment options for PAD are diverse and include both pharmacological and procedural interventions. The use of antiplatelet drugs, lipid-lowering agents, and vasodilators is common in managing PAD, particularly in patients with mild symptoms. However, more severe cases require interventional approaches such as angioplasty, stenting, or bypass surgery. Recently, the advent of minimally invasive techniques , such as drug-coated balloons and stents, has revolutionized treatment by offering quicker recovery times and reduced complications. Additionally, the introduction of novel therapies , including gene therapies and biologics, is expected to change the landscape of PAD management significantly. Emerging trends in the PAD treatment market also include the development of combination therapies , where multiple treatment modalities are used in tandem to improve clinical outcomes. These strategies are designed to address the multifaceted nature of PAD, targeting both the symptoms and underlying causes such as atherosclerosis. Moreover, advancements in personalized medicine are pushing the boundaries of PAD treatment, enabling clinicians to tailor therapies to individual patient profiles, further optimizing therapeutic efficacy, and minimizing adverse effects. Regulatory support is also a key factor fueling market growth, as health authorities across various regions are increasingly approving new treatments and devices for PAD. The approval of drug-eluting devices and biologics is expanding treatment options and improving patient outcomes. However, the market still faces challenges, including the high cost of advanced therapies and limited patient access in rural or low-income regions. Additionally, ongoing clinical trials and research are critical to overcoming the current treatment limitations, which will shape the future direction of the PAD treatment market. In conclusion, the peripheral artery disease treatment market is set for substantial growth, driven by technological innovations, an aging global population, and the increasing focus on improving patient-specific therapeutic strategies. Key stakeholders, including pharmaceutical companies, medical device manufacturers, and healthcare providers, are expected to play pivotal roles in advancing PAD management, while regulatory bodies continue to shape market dynamics with approvals and guidelines. Get a sneak peek at the peripheral artery disease treatment market dynamics @ Peripheral Artery Disease Treatment Market Dynamics Analysis Peripheral Artery Disease Treatment Market Assessment Peripheral Artery Disease Treatment Market Segmentation Peripheral Artery Disease Treatment Market Segmentation By Treatment Type: Devices (Angioplasty Balloons, Angioplasty Stents, Plaque Modification Devices, Hemodynamic Flow Alteration Devices, Peripheral Guidewires), and Drugs Peripheral Artery Disease Treatment Market Segmentation By Distribution Channel: Hospitals, Ambulatory Surgical Centers, and Specialty Clinics Peripheral Artery Disease Treatment Market Segmentation By Geography : North America, Europe, Asia-Pacific, and Rest of World Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s View Which MedTech key players in the peripheral artery disease treatment market are set to emerge as the trendsetter explore @ Peripheral Artery Disease Treatment Companies Table of Contents Interested in knowing the peripheral artery disease treatment market by 2030? Click to get a snapshot of the Peripheral Artery Disease Treatment Market Trends Related Reports Peripheral Artery Disease Epidemiology Forecast Peripheral Artery Disease Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted peripheral artery disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Peripheral Arterial Disease Market Peripheral Arterial Disease Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key PAD companies, including NovoNordisk, Takeda, Mercator MedSystems, Inc., Beijing Northland Biotech. Co., Ltd., Ixaka Ltd, Humacyte, Inc., CardioVascular BioTherapeutics, Proteon Therapeutics, ReNeuron Limited, Alucent Biomedical, Athersys, ARCA biopharma, Ambulero, Venturis Therapeutics , among others. Peripheral Arterial Disease Pipeline Peripheral Arterial Disease Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key peripheral arterial disease companies, including Caladrius Biosciences, Reven Pharmaceuticals, Inc, Helixmith Co., Ltd, among others. Critical Limb Ischemia Market Critical Limb Ischemia Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key critical limb ischemia companies, including Boston Scientific Corporation, AnGes, Inc, Mitsubishi Tanabe Pharma, B. Braun Melsungen AG, among others. Critical Limb Ischemia Pipeline Critical Limb Ischemia Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key critical limb ischemia companies, including Pluristem Therapeutics, Reven Pharmaceuticals, Inc., New Beta Innovation Limited, among others. About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.Founder of failed crypto lending platform Celsius Network pleads guilty to fraud charges
None
NoneEAGLE ELECTRONICS ANNOUNCES FORMATION OF STATE-OF-THE-ART ELECTRONICS MANUFACTURING FACILITY, $14MM OF FUNDING, AND CUSTOMER COMMITMENTS
Stojakovic, Wilkinson lead short-handed Cal past Sacramento State, 83-77 in Cal Classic
Packers' improving run defense ready for challenge against NFC North-leading LionsPackers' improving run defense ready for challenge against NFC North-leading Lions
Gaetz’ Bad Boy image finally catches up with himArtist Jasleen Kaur wins Turner Prize for work exploring her Scottish Sikh identity
None
The unresolved case of JonBenét Ramsey has been the subject of countless documentaries and dramatic television retellings throughout the last 28 years. The latest content about the case is Netflix ‘s “Cold Case: Who Killed JonBenét Ramsey” — a three-part docuseries about the 6-year-old child beauty queen who was brutally murdered on Dec. 26, 1996, in Boulder, Colo. JonBenét’s parents, John and Patsy Ramsey, woke up the morning after Christmas in 1996 and discovered a ransom note in their kitchen. Later that same day, John Ramsey found his daughter’s body in the basement, revealing that JonBenét had not been kidnapped but was instead sexually assaulted and killed in the family home. Soon after, the Boulder police, who had little experience in homicide investigations, quickly turned their suspicions toward the Ramsey family, igniting a media frenzy that painted JonBenét’s parents as the prime suspects. Directed by Oscar-nominated director Joe Berlinger, “Cold Case: Who Killed JonBenét Ramsey” investigates the mishandling of the case by law enforcement and the media. Berlinger chronicles how Boulder police fed the media false information, which led to one-sided reporting that fueled a national obsession with the case. Close to three decades later, no one, including John and Patsy Ramsey, has been charged with the murder of JonBenét. For the documentary, Berlinger spoke to John Ramsey, 80, as well as lawyers and journalists who covered the case. (Patsy Ramsey died in 2006.) The doc also features recordings made by the late Colorado Springs homicide detective Lou Smit, who, after JonBenét’s murder, came out of retirement to help the Boulder DA’s office investigate the case. He left 18 months later because he was frustrated that Boulder Police would not seriously consider that an intruder had killed JonBenét. “No one really has looked at the work of Lou Smit, who I think was a pioneering genius in this space,” says Berlinger. “My series ultimately takes a very strong point of view that the Ramsey’s are innocent and that the police and the media completely abused them.” Although there have been many docs made about JonBenét’s murder, Berlinger says that he never wavered on making “Cold Case: Who Killed JonBenét Ramsey.” “I want to do something when I have something to say, and I feel like I have a number of things to say here,” he says. “Most importantly, I think that this crime can actually be solved.” While previous docs about the crime don’t bother him, Berlinger did admit that the upcoming Paramount+ limited series about the case, which will star Melissa McCarthy and Clive Owen, has him worried. “I am deeply concerned about that production perpetuating false ideas. I don’t know the [route] that they are taking, but it was somewhat shocking for me to hear from John Ramsey that that production hasn’t reached out to him,” says Berlinger. “I don’t want to knock other filmmakers, but Ryan Murphy also had no interest in talking to the Menendez brothers [for ‘Monsters: The Lyle and Erik Menendez Story’], from what I read. If you are going to take on somebody’s life and not talk to them, how do they know the nuances of so many situations?” Variety spoke to Berlinger ahead of the Nov. 25 of “Cold Case: Who Killed JonBenét Ramsey” on Netflix. What needs to be done in this case to move the needle forward? The first is that there were a bunch of crime scene objects that were sent to the crime lab in 1996 but were never tested. We need to do that testing. Also some things were tested, but the technology was primitive at the time. Those things need to be retested. But the most important DNA test that I think would provide a really good opportunity to solve the crime is the existing DNA in the case that involves a mixed sample of JonBenét’s blood and the unidentified male DNA — not linked to any family member — mixed in with her blood. If JonBenét’s DNA is separated from the perpetrator’s DNA, then the perpetrator’s DNA can then be expanded and put into genealogical DNA, like 23andMe. That is a new technology that has been used very successfully and has recently become a major tool for solving cold cases. Is that one of the main reasons why you decided to make this docuseries — to push Colorado authorities to finally take the necessary actions to bring JonBenét Ramsey’s killer to justice? The Ramsey family have been so brutalized for close to 30 years. One of the new things about my show that hasn’t been highlighted in other shows is the degree to which the Boulder Police, who, from day one, “had a feeling” that John Ramsey was the killer, started that suspicion. They couldn’t get off it. Did you approach John Ramsey about making this docuseries, or did he approach you? We approached him. This is not me picking up his advocacy. This is me thinking this would be a good show and reaching out to him and giving him my usual wrap — I have final cut. You will not be paid. You will have no editorial input. He agreed to all of that. You have made several true crime docs, including the “Paradise Lost” trilogy and “Conversations With a Killer: The Ted Bundy Tapes.” How do you feel about true crime sleuths who try to solve murder cases on their own? While it’s not overtly in the show, this [series] was a way for me to comment on the dangers of all these armchair sleuths and people who go down these Reddit rabbit holes. This series was meant to remind people that as popular as true crime is, you always have to remember that there is a victim on the other side. All of these people who are convinced that the family did it and trade in conspiracy theories and half-baked ideas to continue to pound that drum, to me, it’s unethical.
MIDDLEBURY — Northridge 6-foot-6 junior Brady Scholl probably won't ever forget the first boys basketball game at the high school's new Jayco Arena. The 6-foot-6 Scholl filled the stat sheet on Tuesday, as he finished with 22 points, 15 rebounds, eight blocks and two steals to lead the Raiders to an impressive 81-41 win over Elkhart. The game was the season-opener for both teams. Javascript is required for you to be able to read premium content. Please enable it in your browser settings.
Sydney Uni’s U-turn on AI is pragmatic teachingBryant defeats Tennessee State 97-85
The ( ) has been one of the best-performing funds in 2024. But I don't think this will be the end of the long-term gains. As we can see on the chart above, the FANG ETF has climbed a hefty 41% this year. In comparison, the (ASX: XJO) has climbed by 10% — not a bad result, but a significant underperformance to the FANG ETF. Past performance is not a reliable indicator of future performance, of course, and I'm certainly not expecting the FANG ETF to rise another 40% in the next year. But I do believe that this fund, which provides access to leading US technology companies, can beat the ASX 200 again over the next five years. Here's why. While not guaranteed to occur, incoming United States president Donald Trump has indicated he wants to reduce business taxes to 15%, down from 21%. yet. I'm sure more details will come in due course. But I wouldn't be surprised if the businesses inside the FANG ETF see their taxes reduced to some degree, which would boost their . Investors typically value a business on how much profit they're making and could make in the future. A taxation boost to EPS should theoretically boost the share price. The FANG ETF is not known for strong . It has only 10 positions that are designed to be equally weighted. But I think these companies have been and can continue to be wonderful investments. Currently, the FANG portfolio holds these 10 giant technology businesses: These companies are among the best in the world at what they do, whether that's smartphones, device software, social media (such as Instagram), online video, online search, cybersecurity, e-commerce, cloud computing, AI and more. They also typically have strong profit margins, excellent and effective management. Considering the world is becoming increasingly technological, and that these companies are some of the entities driving that change, this area of the global share market is where I'd want at least some of my money, whether that's through the FANG ETF or a different investment. I often say that, in the business world, winners keep winning. Companies like Microsoft, Apple and Alphabet are so far ahead of the competition that it may be almost impossible for others to catch up starting from scratch. With their high , it makes sense for these winners to retain and reinvest profits in improving their products or services and developing new offerings. In my opinion, these companies' rising profits are likely to lead to ongoing capital growth, even if they start with relatively high . The FANG ETF has returned an average of 20% per annum over the past three years. While the next three years aren't guaranteed to be as good, I think the FANG ETF has plenty of capability to outperform the ASX 200.